Enter your keyword

IO Forum
May 10–11, 2024

WELCOME ADDRESS

Dear colleagues,

On behalf of the Organizing Committee, we would like to invite you to participate
in the CENTRAL EUROPEAN LUNG CANCER FORUM 2024 – Immuno-Oncology
in Lung Cancer in Vienna, May 10–11, 2024.

The Forum will provide you with an update on the latest developments in the multimodality treatment of lung cancer with immune checkpoint inhibitors. A major focus will be on adjuvant and neoadjuvant therapies of NSCLC. Novel immunotherapeutic strategies in the palliative settings of NSCLC and SCLC will be covered. The Forum will be interactive and allow for valuable discussion.

The Forum will also offer an opportunity to meet again in person with colleagues and friends. We look forward to welcoming you in Vienna.

Topics

Immune Checkpoint Inhibitors in the Adjuvant Therapy of Resected NSCLC
Neoadjuvant Therapy of Operable NSCLC
Novel Immunotherapy Combinations
Therapeutic Advances in SCLC

Sincerely,
the Organizing Committee

 

IMPORTANT DATES

24 January 2024
Registration opens

10-11 May 2024
CENTRAL EUROPEAN LUNG CANCER FORUM 2024 – Immuno-Oncology in Lung Cancer

VENUE

Austria Trend Parkhotel Schönbrunn
Hietzinger Hauptstr. 10-14, 1130 Vienna, Austria
web: www.austria-trend.at/en/hotels/parkhotel-schoenbrunn

REGISTRATION

ONLINE REGISTRATION

Registration Fee: 150 EUR

Method of Payment
Registration fees must be paid in EUR by the following method:

Bank Transfer

The bank details including the 7-digit payment identifier will be automatically sent to your email address after submitting the online form. Please note that payments without this payment identifier will not be identified and the registration will not be confirmed.

Please note that bank transfer payments will only be accepted by 9 May 2024.

Cancellations and Refunds:
The Organizer must be notified in writing by e-mail at info@wemakemedia.at in the event of the cancellation of the registration. The appropriate refunds will be made after the event.

The following cancellation conditions apply:
before 29 February 2024 — full refund of the registration fee
from 1 March to 31 March 2024 — 50% of the registration fee
from 1 April 2024 — no refund

PROGRAM

SCIENTIFIC GUARANTOR
Central European Lung Cancer Association – CELCA

Program (as of May 6, 2024)

IO_Forum_Vienna_program

ORGANIZING COMMITTEE

Krisztina Bogos, Hungary
Thomas Brodowicz, Austria
Martin Filipits, Austria
Diego Kauffmann-Guerrero, Germany
Rudolf Huber, Germany
Marco Idzko, Austria
Gyula Ostoros, Hungary

Lubos Petruzelka, Czech Republic
Robert Pirker, Austria
Helmut Popper, Austria
Helmut Prosch, Austria
Nevena Secen, Serbia
Martin Svaton, Czech Republic
Milada Zemanova, Czech Republic

TOPICS

Immune Checkpoint Inhibitors in Resected NSCLC
Neoadjuvant Therapy of Operable NSCLC
Novel Immunotherapy Combinations
Therapeutic Advances in SCLC
Satellite Symposia

PARTNERS

AstraZeneca
ProMedican
CEAO
I HOPE

INSTRUCTIONS FOR AUTHORS

  • Please bring your files on a USB flash drive.
  • Save all files related to the presentation in one folder (PowerPoint, movie/video files, etc.).
  • We recommend saving the presentation in PPT format. Please also prepare the presentation in 16:9 format.
  • If you give multiple presentations, save them in different folders and name them in such a way that there can be no misunderstanding when saving them to our system.
  • Submit your lecture directly in the hall where it will be presented (Österreich-Ungarn) at least 1 hour before the start of your session. The technician uploads your presentation to the system, tests it and checks whether it is displayed correctly.

CONTACT

Mgr. Jana Pfeifer
Sponsoring Manager

E-mail: j.pfeifer(at)wemakemedia.at
Cell Phone.: +420 775 852 511

Professional Congress Organizer

We Make Media GmbH
e-mail: info(at)wemakemedia.at
web: www.wemakemedia.eu

You are entering a website intended for the professional medical public

You are entering a website intended for the professional medical public! By entering, you confirm that you are aware that the information contained on the website for medical professionals is not intended for the general public.